GENE ONLINE|News &
Opinion
Blog

2021-08-03| Asia-Pacific

Astellas Makes a $440M+ Pact with Minovia to Develop Mitochondrial Cell Therapies

by Tyler Chen
Share To

Mitochondrial dysfunction is a genetic condition where the mitochondria fail to produce enough energy for the cell and could lead to diseases such as Alzheimer’s disease, muscular dystrophy, cancer, or diabetes. The tricky thing is that the condition could affect most body parts, including the brain, nerves, heart, eyes, or pancreas. Unfortunately, it currently has no cure.

 

A $440+ Million Deal to Challenge the Status Quo

On July 30th, Japan’s Astellas Pharma and Israel-based biotech Minovia Therapeutics announced a $440 million plus deal, aiming to develop and commercialize allogeneic cell therapies for mitochondrial diseases.

As per the terms, Astellas will provide its genetically engineered, induced pluripotent stem cells (iPSCs), a type of cell that can turn into all adult cells, while Minovia will use its mitochondrial augmentation therapy (MAT) platform to develop treatments that infuse healthy mitochondria to the mitochondrial dysfunctional cells and cure the disease.

 

Accelerating Off-the-Shelf Cell Therapy Development

Under the agreement, Minovia will receive $20 million upfront and $420 million per product in future development, regulatory and commercial milestone payments from Astellas.

“We believe this partnership is critical to accelerating the development of off-the-shelf, allogeneic cell therapy programs for the many patients living with mitochondrial diseases caused by mitochondrial dysfunction,” said Minovia’s co-founder and CEO, Natalie Yivgi-Ohana, Ph.D.

It should be noted that the platform is still under clinical trials and is used on patients with Pearson syndrome, one of the mitochondrial diseases, with autologous CD34+ hematopoietic stem cells. The Phase I/II trial began dosing in June 2019 and is the first mitochondrial cell therapy trial to treat mitochondrial disease.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
LATEST
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
2024-05-27
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
EVENT
Scroll to Top